Inventor · disambiguated record
Reginald Christophe Xavier Brys
Also filed as: BRYS REGINALD · BRYS REGINALD C X · BRYS REGINALD CHRISTOPHE XAVIER · BRYS RÉGINALD CHRISTOPHE XAVIER
27 granted patents·16 pending applications·68 citations·filing 2002–2022
95Inventor score
Files withGALAPAGOS NV25BRYS REGINALD CHRISTOPHE XAVIER4MORPHOSYS AG3ANDREWS MARTIN JAMES INGLIS2BRYS REGINALD2
Top patents by PatentIndex Score
43 records- 0192US9670204B2Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disordersGALAPAGOS NV·Filed 2015·Granted Jun 6, 2017·10 cites·20 claims
- 0290US9249141B2Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disordersGALAPAGOS NV·Filed 2014·Granted Feb 2, 2016·9 cites·12 claims
- 0389US11072611B2Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disordersGALAPAGOS NV·Filed 2019·Granted Jul 27, 2021·2 cites·15 claims
- 0489US10125132B2Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disordersGALAPAGOS NV·Filed 2017·Granted Nov 13, 2018·6 cites·20 claims
- 0588US10526329B2Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disordersGALAPAGOS NV·Filed 2018·Granted Jan 7, 2020·4 cites·3 claims
- 0688US8993590B2Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disordersGALAPAGOS NV·Filed 2014·Granted Mar 31, 2015·8 cites·17 claims
- 0786US7306923B2Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseasesGALAPAGOS NV·Filed 2005·Granted Dec 11, 2007·7 cites·11 claims
- 0882US11564923B2Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disordersGALAPAGOS NV·Filed 2018·Granted Jan 31, 2023·2 cites·19 claims
- 0979US9284311B2Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereofVAN T KLOOSTER GERBEN ALBERT ELEUTHERIUS·Filed 2013·Granted Mar 15, 2016·8 cites·6 claims
- 1077US2023022534A1Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disordersGALAPAGOS NV·Filed 2021·Application pending·0 cites
- 1176US8637257B2Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseasesBRYS REGINALD CHRISTOPHE XAVIER·Filed 2008·Granted Jan 28, 2014·3 cites·14 claims
- 1276US7485468B2Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseasesGALAPAGOS BV·Filed 2005·Granted Feb 3, 2009·6 cites·17 claims
- 1373US12472181B2Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disordersGALAPAGOS NV·Filed 2022·Granted Nov 18, 2025·0 cites·3 claims
- 1470US9796719B2Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disordersGALAPAGOS NV·Filed 2014·Granted Oct 24, 2017·1 cites·15 claims
- 1561US8759334B2Compounds useful for the treatment of metabolic and inflammatory diseasesSANIÈRE LAURENT RAYMOND MAURICE·Filed 2012·Granted Jun 24, 2014·2 cites·17 claims
- 1661US7919259B2Methods for identification, and compounds useful for the treatment of degenerative and inflammatory diseasesGALAPAGOS NV·Filed 2007·Granted Apr 5, 2011·0 cites·13 claims
- 1761US2023241068A1Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseasesGALAPAGOS NV·Filed 2022·Application pending·0 cites
- 1856US8097408B2Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseasesBRYS REGINALD·Filed 2009·Granted Jan 17, 2012·0 cites·11 claims
- 1954US10815297B2Antagonists of IL17C for the treatment of inflammatory disordersMORPHOSYS AG·Filed 2018·Granted Oct 27, 2020·0 cites·8 claims
- 2054US8173656B2Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseasesANDREWS MARTIN JAMES INGLIS·Filed 2010·Granted May 8, 2012·0 cites·12 claims
- 2152US12383544B2Methods for the treatment of polycystic kidney diseaseGALAPAGOS NV·Filed 2020·Granted Aug 12, 2025·0 cites·16 claims
- 2252US8178530B2Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseasesANDREWS MARTIN JAMES INGLIS·Filed 2010·Granted May 15, 2012·0 cites·53 claims
- 2352US2021106582A1Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseasesGALAPAGOS NV·Filed 2018·Application pending·0 cites
- 2450US9951337B2Methods and means for treatment of osteoarthritisGALAPAGOS NV·Filed 2016·Granted Apr 24, 2018·0 cites·11 claims
- 2550US2022194938A1Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disordersGALAPAGOS NV·Filed 2020·Application pending·0 cites
- 2650US2022296573A1Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disordersGALAPAGOS NV·Filed 2020·Application pending·0 cites
- 2750US2011118140A1Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseasesGALAPAGOS NV·Filed 2011·Application pending·0 cites
- 2848US10604566B2Antagonists of IL-17C for the treatment and/or prevention of atopic dermatitisMORPHOSYS AG·Filed 2016·Granted Mar 31, 2020·0 cites·6 claims
- 2948US2018127425A1Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disordersGALAPAGOS NV·Filed 2017·Application pending·0 cites
- 3048US2003059794A1Adenoviral library assay for E2F regulatory genes and methods and compositions for screening compoundsFiled 2002·Application pending·0 cites
- 3148US2014200258A1Methods and Means for Treatment of OsteoarthritisBRYS REGINALD CHRISTOPHE XAVIER·Filed 2014·Application pending·0 cites
- 3248US2014371198A1Novel compounds useful for the treatment of metabolic and inflammatory diseasesGALAPAGOS NV·Filed 2014·Application pending·0 cites
- 3348US2014155461A1Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseasesBRYS REGINALD CHRISTOPHE XAVIER·Filed 2013·Application pending·0 cites
- 3446US2003166167A1Adenoviral library assay for E2F regulatory genes and methods and compositions for screening compoundsFiled 2002·Application pending·0 cites
- 3545US2011118338A1Methods, compositions and compound assays for inhibiting amyloid-beta protein productionGALAPAGOS BV·Filed 2011·Application pending·0 cites
- 3644US2022218679A1Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disordersGALAPAGOS NV·Filed 2020·Application pending·0 cites
- 3743US8663930B2Methods and means for treatment of osteoarthritisBRYS REGINALD CHRISTOPHE XAVIER·Filed 2010·Granted Mar 4, 2014·0 cites·7 claims
- 3842US12264156B2Compounds and pharmaceutical compositions thereof for the treatment of diseasesGALAPAGOS NV·Filed 2019·Granted Apr 1, 2025·0 cites·20 claims
- 3942US8673268B2Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseasesBRYS REGINALD·Filed 2012·Granted Mar 18, 2014·0 cites·8 claims
- 4040US2014243506A1Antagonists of il17c for the treatment of inflammatory disordersMORPHOSYS AG·Filed 2012·Application pending·0 cites
- 4137US10508111B26-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-B]pyridin-3-yl]-nicotinonitrile derivatives and their use as IRAK inhibitorsGALAPAGOS NV·Filed 2016·Granted Dec 17, 2019·0 cites·15 claims
- 4236US2016296529A1Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereofVAN'T KLOOSTER GERBEN ALBERT ELEUTHERIUS·Filed 2016·Application pending·0 cites
- 4334US9945843B2Methods for identifying compounds that inhibit G protein-coupled receptor (GPR84) agonist-stimulated chemotaxisGALAPAGOS NV·Filed 2012·Granted Apr 17, 2018·0 cites·15 claims
Join the waitlist — get patent alerts
Get an alert when Reginald Christophe Xavier Brys files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →